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a b s t r a c t
Multi-target inhibitors have become increasing popular as a means to leverage the advantages of poly-
pharmacology while simplifying drug delivery. Here, we describe dual inhibitors for soluble epoxide
hydrolase (sEH) and fatty acid amide hydrolase (FAAH), two targets known to synergize when treating
inflammatory and neuropathic pain. The structure activity relationship (SAR) study described herein ini-
tially started with t-TUCB (trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-cyclohexyloxy]-benzoic acid),
a potent sEH inhibitor that was previously shown to weakly inhibit FAAH. Inhibitors with a 6-fold
increase of FAAH potency while maintaining high sEH potency were developed by optimization.
Interestingly, compared to most FAAH inhibitors that inhibit through time-dependent covalent modifica-
tion, t-TUCB and related compounds appear to inhibit FAAH through a time-independent, competitive
mechanism. These inhibitors are selective for FAAH over other serine hydrolases. In addition, FAAH inhi-
bition by t-TUCB appears to be higher in human FAAH over other species; however, the new dual sEH/
FAAH inhibitors have improved cross-species potency. These dual inhibitors may be useful for future
studies in understanding the therapeutic application of dual sEH/FAAH inhibition.
 2018 Elsevier Ltd. All rights reserved.
Chronic pain is poorly managed by current treatment options.
The available therapies, including non-steroidal anti-inflammatory
drugs (NSAIDs) and opioids, are not effective on all types of pain,
can be debilitating or have a high potential for abuse.1 Further-
more, few new therapies have come to the market in the past dec-
ade. One recent approach towards designing analgesics with high
efficacy and reduced side effects has been the combination of inhi-
bitors for two or more targets known to regulate pain, known as
poly-pharmacology.2 These multi-target inhibitors have the poten-
tial for higher efficacy and reduced drawbacks arising from the use
of a single-target drug or a combination of multiple drugs.3 In par-
ticular, enzymes involved in the regulation of signaling lipids,
including soluble epoxide hydrolase (sEH) and fatty acid amide
hydrolase (FAAH), have been proposed as suitable targets for the
application of poly-pharmacology for pain treatment.4,5
The sEH is responsible for the regulation of lipid epoxides acting
as potent chemical mediators such as epoxyeicosatrienoic acids
(EETs).6 These signaling lipids are responsible for mediating a
number of biological processes including nociception,7,8 inflamma-
tion9 and hypertension.10,11 By converting the biologically active
epoxides to their respective largely inactive diols, sEH negatively
regulates the activity of the EETs. The in vivo stability of EETs
and other chemically stable epoxy-fatty acids is low due to the
high catalytic efficiency of sEH.12 Thus, sEH inhibition has been
the major approach for studying the biological role of lipid epox-
ides in numerous disease states including neuropathic and inflam-
matory pain.13,14 Treating with sEH inhibitors reduces both forms
of pain in a manner that may be dependent, in part, on cannabinoid
signaling,15 endoplasmic reticulum stress16 and/or other mecha-
nisms. Several of these inhibitors have been developed as IND can-
didates that have reached Phase I (GSK2256294A) and Phase II
(AR9281) clinical trials for COPD and hypertension, respectively
(Fig. 1).17–19 GSK2256294A has not progressed to further stages
https://doi.org/10.1016/j.bmcl.2018.01.003
0960-894X/ 2018 Elsevier Ltd. All rights reserved.
Abbreviations: AADAC, arylacetamide deacetylase; AEA, arachidonoyl ethanola-
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of clinical trials and AR9281 was unable to demonstrate efficacy in
human patients.
FAAH is a separate enzyme that is studied as a potential thera-
peutic target for neuropathic and inflammatory pain.20–22 This
enzyme hydrolyzes arachidonoyl ethanolamide (AEA), an endo-
cannabinoid that regulates nociception and other physiologies
through activation of the cannabinoid receptors.22,23 Like EETs,
AEA is quickly metabolized in vivo by FAAH and therefore in vivo
studies investigating AEA require FAAH inhibitors. Although acti-
vation of cannabinoid receptors has numerous undesired effects
including hypothermia, catalepsy and hyperphagia, treatment with
FAAH inhibitors or AEA alone is not sufficient for producing these
effects.24,25 Several FAAH inhibitors have been developed. Among
them, PF-04457845 reached Phase II clinical trials without success
due to lack of efficacy despite its excellent target engagement.26
Recently, BIA 10-2474 was also pulled from a Phase I clinical trial
after the death of a study subject,27 which was independent of
FAAH inhibition.28
Concurrent inhibition of both sEH and FAAH synergistically
reduces both inflammatory and neuropathic pain.29 Interestingly,
the sEH inhibitor trans-4-[4-(3-trifluoromethoxyphenyl-l-ureido)-
cyclohexyloxy]-benzoic acid (t-TUCB), which was thought to be a
selective potent sEH inhibitor (IC50 = 0.4 nM), was recently identi-
fied as a weak FAAH inhibitor (human FAAH IC50 = 260 nM).
t-TUCB demonstrates excellent efficacy with multiple indications
including neuropathic pain, but it was not clear whether its high
efficacy is derived from its poly-pharmacology. This excellent effi-
cacy has led to its use as a tool to treat various diseases30–32 in sev-
eral animal species.33,34 Despite the extensive use of this
compound for studying sEH biology, the contribution of FAAH inhi-
bition to results in the experimental or clinical disease models has
not been explored. Thus, our primary goal was to produce novel
inhibitors with improved potency towards sEH and FAAH. Our
secondary goal was to test the plausibility of FAAH inhibition con-
tributing to the observed beneficial effects of t-TUCB and related
compounds by defining the potency for dual inhibition in other
species.
Synthesis of all inhibitors was done according to established
procedures (described in detail in the Supplementary Material).
Recombinant enzyme preparations were used with fluorescent-
based substrates to quantify potency of inhibitors on sEH and
FAAH (described in the Supplementary Material). All of the newly
synthesized inhibitors are relatively potent towards sEH (IC50 <50
nM) as expected. Thus, we primarily focused on determining the
chemical structures essential for optimizing potency on FAAH.
Compared to the known FAAH inhibitors PF-3845 and URB597, t-
TUCB is 233-fold and 6-fold less potent, respectively (Table 1).20,35
Rings ‘‘A” and ‘‘B” and substituents on the 4-position of ‘‘C” were
modified on t-TUCB to determine the portion of the structure that
primarily confers potency on FAAH (Fig. 1B). Urea-based FAAH
inhibitors described previously have an aromatic substitution on
one side of the urea, similar to ring ‘‘A” on t-TUCB. Since these com-
pounds had higher potency for the 4-fluoro or unsubstituted rings
than the 4-trifluoromethoxy substituent,36 the 4-trifluoromethoxy
group on t-TUCB was replaced by a hydrogen (2), fluoride (3) or
chloride (4). Potency on FAAH decreased as the size and hydropho-
bicity of the para position substituent increased, with 4-trifluo-
romethoxy (1) being the most potent. Substituting the aromatic
ring for a cyclohexane (5) or adamantane (6) resulted in a complete
loss in activity against FAAH. Switching the cyclohexane linker of
ring ‘‘B” to a cis conformation (c-TUCB) resulted in a 20-fold loss
of potency while replacing it with a butane chain (9) resulted in
a completely inactive compound. Modification of the cyclohexane
to an aromatic linker (10) had essentially no effect on potency
for FAAH relative to t-TUCB. Although many potent urea-based
FAAH inhibitors use a piperidine as the carbamoylating
nitrogen,21,37,38 the modification to piperidine-incorporated
tri-substituted urea reduced potency 13-fold (13). Together, these
changes on ring ‘‘B” indicate the trans-cyclohexyl ring provides the
exact fit in the active site of FAAH essential for t-TUCB’s inhibitory
potency.
To further explore the relationship between structure and func-
tion on the FAAH enzyme, we focused on the substitutions on the
4-position of ring ‘‘C” (Table 2). The importance of the terminal car-
boxylic acid group was explored by testing the potency of the cor-
responding aldehyde (15) and alcohol (16) in addition to the amide
(21) and nitrile (14). Generally, the higher oxidation state of the
terminal portion correlates with higher potency towards FAAH.
t-TUCB was 10-times more potent than 15 and 50-times more
potent than 16. Similarly, the amide (21) was over 100-times more
potent than the nitrile (14). Converting the benzoic acid to the phe-
nol (18) had a minor effect on potency. Interestingly, modifying the
phenol to the anisole (19) completely removed activity while cre-
ating an acetate ester (20) is equipotent to the phenol. Since the
substrates for FAAH tend to be relatively hydrophobic lipids, we
speculated conversion of the acid and primary amide to the corre-
sponding esters or substituted amides, respectively, would result
in improved potency by introducing hydrophobic groups. As
expected, the methyl ester (22) had 4-fold improved potency rela-
tive to the corresponding acid (t-TUCB). However, incorporating a
bulkier substitution than the methyl group such as isopropyl ester
(23) showed 11-fold less potency compared to the methyl ester
(22). Interestingly, the benzyl ester (24) gives approximately the
same potency as the methyl ester, suggesting that p-p stacking
between benzylic group and a residue at the active site may be
important. Relative to t-TUCB, the methyl (25), ethyl (26) and gly-
cinyl (27) amides all had essentially the same potency; however,
the benzyl amide (29) was substantially less potent (16-fold).
Between the methyl- (22 and 25) and benzyl-substituted (24 and
Fig. 1. A. Structures of several sEH inhibitors (t-TUCB, TPPU, GSK2256294A,
AR9281) and FAAH inhibitors (URB597, PF-3845, PF-04457845) B. Modifications
of t-TUCB skeleton were tested at the trifluoromethoxyphenyl group (‘‘Ring A”), the
trans cyclohexyl group (‘‘Ring B”) or the benzoic acid (‘‘Ring C”).
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29) compounds, the esters generally appear to be more potent than
the amides. This difference in the potency may be due to the speci-
fic angle of the substituted groups or the increased electron density
of the ester carbonyl compared to the amide carbonyl. Generating
the methyl ester of the glycinyl amide (28) increased the potency
4-fold compared to the corresponding free acid. Since the amide
and esters appeared to be active, the amide bioisostere oxadiazole
(17) was tested and had 38-fold less potency than the initial com-
pound. Many compounds in this series could act as prodrugs fol-
lowing esterase or amidase catalyzed hydrolysis.39
Many FAAH inhibitors work through carbamoylation of the cat-
alytic serine residue.20,36,40 Inhibition through this mechanism is
time-dependent because the inhibitory potency depends on the
rate of carbamoylation. However, to our surprise, the potency of
t-TUCB and two new inhibitors (18 and 24) does not change with
time (Fig. 2A), suggesting that these inhibitors are unlikely to inhi-
bit through the formation of a covalent intermediate. URB597, an
inhibitor known to carbamoylate FAAH, has a 3-fold increase in
potency over the same period of time. To further test the
mechanism of action of these inhibitors we determined the effect
of varying substrate concentrations on the inhibitory potency of
t-TUCB (Fig. 2B). Results showed an increase in KMapp with only a
minor change in vmaxapp indicating that inhibition primarily occurs
through a competitive mechanism. Assuming a simple competitive
model, the calculated Ki for t-TUCB is 156 ± 85 nM. Using the same
analysis, the Ki for 18 and 24 are 9.1 ± 2.5 nM and 43 ± 25 nM,
respectively.
Since the endogenous substrates, EETs and AEA, for sEH and
FAAH, respectively, share the arachidonic acid backbone, it is rea-
sonable to speculate t-TUCB may competitively inhibit FAAH by
mimicking and displacing the substrate. Although these lipids are
linear carbon chains, a folded orientation in the substrate tunnel
may resemble the linked-ring structure of t-TUCB. The crystal
structure of methoxy arachidonoyl phosphonate (MAP) bound to
FAAH demonstrates the bound substrate is not linear in the active
site but bends around the unsaturated bonds.41 To investigate this
possibility, we docked t-TUCB, 18 and 24 into the FAAH active site
using AutoDock Vina (Fig. 3A and Supplementary Fig. 1). Docking
Table 1
Potency of inhibitors with modifications on Ring A (R1) and Ring B (R2) against both human sEH and human FAAH.
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in the FAAH active site, the polar aromatic groups on t-TUCB, 18
and 24 form hydrogen-bond interactions with the catalytic serine
and orient in a manner similar to its lipid substrates when docked
in the FAAH active site. In the case of t-TUCB and 18, the A ring
occupies the acyl-binding pocket of the active site; while 24 stays
in the membrane access channel. The binding orientation from
docking t-TUCB and 18 is similar to the co-crystal structure
described for covalently bound PF-384520 and is consistent with
the SAR described in this manuscript. If the 4-trifluo-
romethoxyphenyl group on ring A occupies the acyl-binding
pocket, then modification of this group to bulky lipophilic groups
such as an adamantyl group will be not suitable for this site and
modification to smaller groups such as an unsubstituted phenyl
will decrease the ability to stably occupy that pocket. Further,
modification of ring B will either decrease the stability of that con-
formation in the case of the butane chain or force the molecule to
unfavorable conformation in the case of the cis form of TUCB (c-
TUCB) and the tri-substituted urea (13). Finally, modifications to
the 4-substituent on ring C determine potency based on the inter-
actions required to generate an acyl-intermediate; thus, we would
predict a highly electrophilic organophosphate or trifluo-
romethylketone analogues that mimic these acyl-intermediates
may improve the potency of future inhibitors.42,43
By comparison, the disubstituted urea on t-TUCB is known to
form strong hydrogen bonds with the catalytic aspartate residue
and the H-bond donating tyrosine residues in the active site of
the sEH enzyme.44 In the co-crystallization of t-TUCB in the active
Table 2





















Fig. 2. A. t-TUCB, 18, 24 and URB597 were pre-incubated with FAAH enzyme at
various time intervals followed by addition of substrate ([S]final = 5 lM). Potency of
t-TUCB, 18 or 24 inhibition is independent on pre-incubation time while inhibition
by URB597 is time dependent. B. Reaction kinetics of OMP hydrolysis by FAAH was
measured at various [OMP] and [t-TUCB] to determine inhibition mechanism. As
[t-TUCB] increases the KMapp substantially increases (from KMapp = 30 lM to KMapp >200
lM) and the vmax marginally increases (4.0 to 5.4 RFU/s), consistent with a
primarily competitive mechanism of inhibition.
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site of sEH (Fig. 3B) the urea fits between the aspartate and the two
tyrosine residues. The flanking pockets on either side of the cat-
alytic site are large and can accommodate a variety of shapes. Thus,
consistent with the SAR, a large variety of shapes may be accom-
modated by sEH on either side of the urea and potency will remain
relatively high (IC50 <50 nM). The atomic coordinates and structure
factors (code 6AUM) have been deposited in the Protein Data Bank,
Research Collaboratory for Structural Bioinformatics, Rutgers
University, New Brunswick, NJ (http://www.rcsb.org/).
To test the selectivity of these inhibitors toward FAAH, we
investigated their ability to inhibit a series of related enzymes,
especially serine hydrolases (Table 3). t-TUCB, 18, or 24 did not
inhibit the tested carboxylesterases (hCE1 and hCE2), hydrolases
involved in xenobiotic detoxification, or paraoxonases (PON1,
PON2 and PON3), esterases involved in the regulation of
artherosclerosis,45 but 18 did partially inhibit arylacetamide
deacetylase (AADAC), a poorly characterized enzyme that is known
to metabolize several xenobiotics.46 These results indicate that,
unlike most known FAAH inhibitors that have poor selectivity
against other serine hydrolases,47,48 broad off-target inhibition of
other serine hydrolases by t-TUCB, 18 and 24 is unlikely.
t-TUCB has been used extensively for studying the role of sEH in
multiple animal models of pain.33,34,49 To test whether potency
towards FAAHmay account for the efficacy in these animal models,
the effectiveness of t-TUCB, 18 and 24 to inhibit FAAH was mea-
sured on other species than human using brain microsome prepa-
rations. As positive controls, the IC50 values of two well
characterized FAAH inhibitors, PF-3845 and URB-597 were mea-
sured also (Table 4, Supplementary Data). These two inhibitors
are structurally distinct and have excellent selectivity in rat brain
microsomes for the FAAH enzyme over other hydrolases.20,38 As
expected, both inhibitors blocked >80% of the activity in the micro-
somes of the different species tested (Supplementary Fig. 2). Inter-
estingly, both t-TUCB and 24 are less potent against the FAAH of all
other species tested than human FAAH. 18 had comparable IC50s
for FAAH from all species tested except from rat, where 18 is 10–
fold less potent. The hypothesized mechanism of inhibition based
on docking relies on a relatively specific fit in the enzyme active
site. Thus, we speculate small modifications to this acyl-binding
pocket across species accounts for the substantial species selectiv-
ity observed for these inhibitors. By comparison, sEH inhibition
relies primarily on strong hydrogen-bonding interactions and less
on enzyme fit. t-TUCB, 18 and 24 also had species differences on
sEH but all three inhibitors were still relatively potent in all species
tested (IC50 <100 nM). Due to the low potency towards FAAH rela-
tive to sEH (Table 4), it is unlikely that FAAH inhibition contributes
to the previously observed effects of t-TUCB on pain in a mouse
model.49
In conclusion, we have designed dual sEH/FAAH inhibitors with
nanomolar potency towards both enzymes. These inhibitors have
potency independent of incubation time and a mechanism consis-
tent with competitive inhibition. Furthermore, these inhibitors are
Fig. 3. A. Docking of t-TUCB (yellow) in the active site of FAAH (PDB: 1MT5) using
AutoDock Vina and B. Co-crystal structure of t-TUCB (yellow) in the active site of
sEH. The key catalytic residues for FAAH (Ser241) and sEH (Asp335) are represented
in addition to the proton-donating residue on sEH (Tyr 383 and Tyr466). Hydrogen
bonds are represented on the co-crystal structure as yellow dashed lines.
Table 3
IC50 values of compounds t-TUCB, 18 and 24 on other human serine hydrolases.
Enzyme IC50 (nM)
t-TUCB 18 24
FAAH 140 120 24
sEH 0.8 2 3
mEH >10,000 >10,000 >10,000
hCE1 >10,000 >10,000 >10,000
hCE2 >10,000 >10,000 >10,000
PON1 >10,000 >10,000 >10,000
PON2 >10,000 >10,000 >10,000
PON3 >10,000 >10,000 >10,000
AADAC >10,000 5400 >10,000
Table 4
IC50 values of compounds t-TUCB, 18 and 24 on sEH and FAAH in multiple species.
Enzyme Species IC50 (nM)
t-TUCB 18 24 PF-3845 URB597
FAAH Human 140 120 24 0.6 23
Mouse 6300 350 510 12 11
Rat >10,000 1700 >10,000 4.4 12
Cat 1200 92 240 <0.1 12
Dog 3900 280 280 0.4 22
Horse 3300 270 87 0.3 7
sEH Human 0.8 2 3 – –
Mouse 5.7 0.4 2.1 – –
Rat 54 1.0 1.6 – –
Cat 2.0 4.3 42 – –
Dog 5.6 11 28 – –
Horse 19 21 77 – –
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selective for FAAH over other serine hydrolases and have relatively
low species selectivity. Use of these inhibitors will support future
biological studies investigating the importance of dual sEH/FAAH
inhibition.
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